Century Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Century Therapeutics (NASDAQ:IPSC) Full Year 2024 Results

Key Financial Results

• Net loss: US$126.6m (loss narrowed by 7.4% from FY 2023).
• US$1.61 loss per share (improved from US$2.30 loss in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Century Therapeutics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 97%. Earnings per share (EPS) missed analyst estimates by 17%.

Looking ahead, revenue is expected to decline by 40% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%.

Performance of the American Biotechs industry.

The company's shares are down 1.5% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 4 warning signs for Century Therapeutics (of which 2 are potentially serious!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.